Idorsia reveals it is working with Neurocrine on new epilepsy drug deal
pharmafile | January 10, 2020 | News story | Medical Communications | FDA, Idorsia, Neurocrine, drugs, epilepsy, pharma
Idorsia revealed its 2019 deal for its investigational epilepsy medicine was with Neurocrine Biosciences, and it is potentially worth more than $400 million.
The agreement calls for Idorsia to get $365 million in development, $45 million in cash and $7 million in research. It will also get regulatory milestone payments if Neurocrine exercises its option within 30 days of the FDA accepting an investigational new drug application, which is expected for mid-2020. There would also be royalties for its epilepsy drug, known as ACT-709478.
The drug is designed to target calcium channels throughout the central nervous system believed to play a role in epilepsy. It has completed an early safety study in healthy adults, and is slated to start a Phase 2 trial in rare paediatric epilepsy this year.
Kevin Gorman, Neurocrine CEO, said: “We are excited to leverage the scientific expertise of Idorsia in T-type calcium channel inhibition to potentially advance a Phase 2 ready compound to help people suffering from epilepsy.”
In 2019, Idorsia got a $5 million payment for a licensing option for ACT-709478, but they did not reveal Neurocrine’s identity.
Conor Kavanagh
Related Content
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …
GSK’s meningococcal vaccine candidate accepted for FDA review
GSK has announced that the US Food and Drug Administration (FDA) has accepted for review …
FDA grants ODD to Candel Therapeutics’ pancreatic cancer treatment
Candel Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan …